Catalysts · REGN · CIK 872589 · page 2 of 3

REGN catalysts and FDA events, page 2.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on REGN PDUFA dates and upcoming catalysts. This page continues the list.

Upcoming catalysts (continued)

DateDrugCompanyEventIndicationStatusSource
October 2028Month disclosedpozelimab (REGN3918)REGNPrimary completionParoxysmal Nocturnal HemoglobinuriaScheduledClinicalTrials.gov
October 2028Month disclosedaln-ang3REGNPrimary completionDiabetic Kidney Disease (DKD)ScheduledClinicalTrials.gov
Nov 2028 to Feb 2029Quarter disclosedolatorepatide (HS-20094)REGNTopline readoutHidradenitis SuppurativaScheduledClinicalTrials.gov
November 2028Month disclosedolatorepatide (HS-20094)REGNPrimary completionHidradenitis SuppurativaScheduledClinicalTrials.gov
Dec 2028 to Mar 2029Quarter disclosedolatorepatide (HS-20094)REGNTopline readoutOverweight or Obesity Without DiabetesScheduledClinicalTrials.gov
December 2028Month disclosedolatorepatide (HS-20094)REGNPrimary completionOverweight or Obesity Without DiabetesScheduledClinicalTrials.gov
Jan to Apr 2029Quarter disclosedaln-cidebREGNTopline readoutMetabolic Dysfunction-Associated Steatohepatitis; MASHScheduledClinicalTrials.gov
January 2029Month disclosedaln-cidebREGNPrimary completionMetabolic Dysfunction-Associated Steatohepatitis; MASHScheduledClinicalTrials.gov
Mar to Jun 2029Quarter disclosedcenvacibart (REGN7508)REGNTopline readoutAtrial Fibrillation (AF)ScheduledClinicalTrials.gov
Mar to Jun 2029Quarter disclosedaln-cidebREGNTopline readoutMetabolic Dysfunction-Associated Steatotic Liver Disease; MASLDScheduledClinicalTrials.gov
March 2029Month disclosedaln-cidebREGNPrimary completionMetabolic Dysfunction-Associated Steatotic Liver Disease; MASLDScheduledClinicalTrials.gov
March 2029Month disclosedcenvacibart (REGN7508)REGNPrimary completionAtrial Fibrillation (AF)ScheduledClinicalTrials.gov
May to Aug 2029Quarter disclosedLynozyfic (linvoseltamab)REGNTopline readoutRelapsed and/or Refractory Multiple Myeloma (RRMM)ScheduledClinicalTrials.gov
May to Aug 2029Quarter disclosedregn-2catREGNTopline readoutAllergic ConjunctivitisScheduledClinicalTrials.gov
May to Aug 2029Quarter disclosedaln-cidebREGNTopline readoutAlcohol-Associated Liver Disease; ALDScheduledClinicalTrials.gov
May 2029Month disclosedaln-cidebREGNPrimary completionAlcohol-Associated Liver Disease; ALDScheduledClinicalTrials.gov
May 2029Month disclosedLynozyfic (linvoseltamab)REGNPrimary completionRelapsed and/or Refractory Multiple Myeloma (RRMM)ScheduledClinicalTrials.gov
May 2029Month disclosedregn-2catREGNPrimary completionAllergic ConjunctivitisScheduledClinicalTrials.gov
Jun to Sep 2029Quarter disclosedcenvacibart (REGN7508)REGNTopline readoutVenous Thromboembolism (VTE)ScheduledClinicalTrials.gov
June 2029Month disclosedcenvacibart (REGN7508)REGNPrimary completionVenous Thromboembolism (VTE)ScheduledClinicalTrials.gov
Jul to Oct 2029Quarter disclosedOrdspono™ (odronextamab)REGNTopline readoutFollicular Lymphoma (FL)ScheduledClinicalTrials.gov
July 2029Month disclosedOrdspono™ (odronextamab)REGNPrimary completionFollicular Lymphoma (FL)ScheduledClinicalTrials.gov
Aug to Nov 2029Quarter disclosedcenvacibart (REGN7508)REGNTopline readoutPeripheral Artery Disease (PAD)ScheduledClinicalTrials.gov
August 2029Month disclosedcenvacibart (REGN7508)REGNPrimary completionPeripheral Artery Disease (PAD)ScheduledClinicalTrials.gov
Sep to Dec 2029Quarter disclosedcenvacibart (REGN7508)REGNTopline readoutAtrial Fibrillation (AF)ScheduledClinicalTrials.gov
September 2029Month disclosedcenvacibart (REGN7508)REGNPrimary completionAtrial Fibrillation (AF)ScheduledClinicalTrials.gov
Dec 2029 to Mar 2030Quarter disclosedREGN10597REGNTopline readoutNon Small Cell Lung Cancer; NSCLCScheduledClinicalTrials.gov
Dec 2029 to Mar 2030Quarter disclosedcenvacibart (REGN7508)REGNTopline readoutSecondary StrokeScheduledClinicalTrials.gov
December 2029Month disclosedREGN10597REGNPrimary completionNon Small Cell Lung Cancer; NSCLCScheduledClinicalTrials.gov
December 2029Month disclosedcenvacibart (REGN7508)REGNPrimary completionSecondary StrokeScheduledClinicalTrials.gov
Jan to Apr 2030Quarter disclosedfianlimab (REGN3767)REGNTopline readoutNon-small Cell Lung CancerScheduledClinicalTrials.gov
Jan to Apr 2030Quarter disclosedpozelimab (REGN3918)REGNTopline readoutParoxysmal Nocturnal HemoglobinuriaScheduledClinicalTrials.gov
Jan to Apr 2030Quarter disclosedcenvacibart (REGN7508)REGNTopline readoutCancer-Associated Thrombosis (CAT)ScheduledClinicalTrials.gov
January 2030Month disclosedfianlimab (REGN3767)REGNPrimary completionNon-small Cell Lung CancerScheduledClinicalTrials.gov
January 2030Month disclosedpozelimab (REGN3918)REGNPrimary completionParoxysmal Nocturnal HemoglobinuriaScheduledClinicalTrials.gov
January 2030Month disclosedcenvacibart (REGN7508)REGNPrimary completionCancer-Associated Thrombosis (CAT)ScheduledClinicalTrials.gov
Mar to Jun 2030Quarter disclosedaln-pnpREGNTopline readoutMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)ScheduledClinicalTrials.gov
March 2030Month disclosedaln-pnpREGNPrimary completionMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)ScheduledClinicalTrials.gov
May to Aug 2030Quarter disclosedLibtayo® (cemiplimab)REGNTopline readoutCutaneous Squamous Cell Carcinoma (CSCC)ScheduledClinicalTrials.gov
May 2030Month disclosedLibtayo® (cemiplimab)REGNPrimary completionCutaneous Squamous Cell Carcinoma (CSCC)ScheduledClinicalTrials.gov
Jun to Sep 2030Quarter disclosedubamatamab (REGN4018)REGNTopline readout—ScheduledClinicalTrials.gov
June 2030Month disclosedubamatamab (REGN4018)REGNPrimary completion—ScheduledClinicalTrials.gov
Jul to Oct 2030Quarter disclosedPasatru (garetosmab)REGNTopline readoutFibrodysplasia Ossificans Progressiva; FOPScheduledClinicalTrials.gov
July 2030Month disclosedPasatru (garetosmab)REGNPrimary completionFibrodysplasia Ossificans Progressiva; FOPScheduledClinicalTrials.gov
Oct 2030 to Jan 2031Quarter disclosedfianlimab+cemiplimab (REGN3767)REGNTopline readoutMelanomaScheduledClinicalTrials.gov
October 2030Month disclosedfianlimab+cemiplimab (REGN3767)REGNPrimary completionMelanomaScheduledClinicalTrials.gov
Nov 2030 to Feb 2031Quarter disclosedLibtayo® (cemiplimab)REGNTopline readoutLocally Advanced Basal Cell CarcinomaScheduledClinicalTrials.gov
November 2030Month disclosedLibtayo® (cemiplimab)REGNPrimary completionLocally Advanced Basal Cell CarcinomaScheduledClinicalTrials.gov

Past catalysts and FDA decisions (continued)

DateDrugCompanyEventIndicationStatusSource
Dec 2025Month disclosed—REGNNDA/BLA submissionprofound genetic hearing loss in children due to variants of the otoferlinCompletedSEC 8-K Exhibit 99.1
November 19, 2025PAVBLU® (aflibercept)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
Nov 2025Month disclosedEylea®REGNPDUFA datemacular edemaScheduledSEC 8-K Exhibit 99.1
Nov 2025Month disclosedEylea®REGNFDA approvalwith RVO with up to every 8-week dosingApprovedSEC 8-K Exhibit 99.1
October 29, 2025Libtayo (cemiplimab-rwlc)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
October 28, 2025—REGNEarnings—CompletedSEC 8-K Exhibit 99.1
October 15, 2025REGN5381REGNPrimary completionUncontrolled HypertensionWithdrawnClinicalTrials.gov
October 9, 2025Praluent (alirocumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
October 8, 2025Libtayo (cemiplimab-rwlc)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
Oct 2025Month disclosedLibtayo® (cemiplimab)REGNPDUFA date—ScheduledSEC 8-K Exhibit 99.1
September 25, 2025Evkeeza (evinacumab-dgnb)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
September 17, 2025REGN5381REGNPrimary completionHeart FailureWithdrawnClinicalTrials.gov
Sep 2025Month disclosed—REGNInterim readout—ScheduledSEC 8-K Exhibit 99.1
Sep 2025Month disclosedEvkeeza® (evinacumab)REGNFDA approvalhomozygous familial hypercholesterolemiaApprovedSEC 8-K Exhibit 99.1
August 26, 2025PAVBLU® (aflibercept)REGNPrimary completionNeovascular Age-Related Macular Degeneration; Diabetic Macular EdemaCompletedClinicalTrials.gov
August 19, 2025—REGNPDUFA date—ScheduledSEC 8-K Exhibit 99.1
August 1, 2025—REGNEarnings—CompletedSEC 8-K Exhibit 99.1
Aug 2025Month disclosedEylea®REGNPDUFA datemacular edemaCRL issuedSEC 8-K Exhibit 99.1
July 30, 2025Ordspono™ (odronextamab)REGNComplete Response Letter—CRL issuedSEC 8-K Exhibit 99.1
July 30, 2025—REGNPDUFA date—ScheduledSEC Form 10-Q
July 30, 2025Ordspono™ (odronextamab)REGNPDUFA date—CRL issuedSEC 8-K Exhibit 99.1
July 17, 2025Pasatru (garetosmab)REGNPrimary completionFibrodysplasia Ossificans ProgressivaCompletedClinicalTrials.gov
July 10, 2025Lynozyfic (linvoseltamab)REGNPDUFA date—ScheduledSEC 8-K Exhibit 99.1
July 8, 2025pozelimab + cemdisiranREGNPrimary completionGeneralized Myasthenia GravisCompletedClinicalTrials.gov
2H 2025Half-year disclosedDupixent (dupilumab)REGNPDUFA date—ScheduledSEC 8-K Exhibit 99.1
2H 2025Half-year disclosedZepbound (tirzepatide)REGNInterim readout—ScheduledSEC 8-K Exhibit 99.1
2H 2025Half-year disclosedfianlimab (REGN3767)REGNNDA/BLA submission—ScheduledSEC 8-K Exhibit 99.1
June 20, 2025Dupixent (dupilumab)REGNPDUFA date—ApprovedSEC 8-K Exhibit 99.1
June 18, 2025Dupixent (dupilumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
June 2, 2025REGN5381REGNPrimary completionHeart FailureCompletedClinicalTrials.gov
Jun 2025Month disclosedDupixent (dupilumab)REGNFDA approvalwith bullous pemphigoidApprovedSEC 8-K Exhibit 99.1
May 10, 2025REGN1908REGNPrimary completionAllergic ConjunctivitisCompletedClinicalTrials.gov
April 29, 2025—REGNEarnings—CompletedSEC 8-K Exhibit 99.1
April 23, 2025Eylea®REGNComplete Response Letter—CRL issuedSEC 8-K Exhibit 99.1
April 20, 2025Eylea®REGNPDUFA date—CRL issuedSEC 8-K Exhibit 99.1
April 20, 2025—REGNPDUFA date—ScheduledSEC 8-K Exhibit 99.1
April 18, 2025Dupixent (dupilumab)REGNPDUFA dateand adolescents aged 12 years and older with chronic spontaneous urticariaApprovedSEC 8-K Exhibit 99.1
April 17, 2025Dupixent (dupilumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
Apr 2025Month disclosedfianlimab (REGN3767)REGNInterim readout—ScheduledSEC Form 10-Q
Apr 2025Month disclosedDupixent (dupilumab)REGNFDA approvaland adolescents aged 12 years and older with CSUApprovedSEC 8-K Exhibit 99.1
February 4, 2025—REGNEarnings—CompletedSEC 8-K Exhibit 99.1
Feb 2025Month disclosedDupixent (dupilumab)REGNNDA/BLA accepted—CompletedSEC 8-K Exhibit 99.1
Jan 2025Month disclosedOrdspono™ (odronextamab)REGNNDA/BLA submission—CompletedSEC 8-K Exhibit 99.1
Q1 2025Quarter disclosedEylea®REGNNDA/BLA submission—ScheduledSEC 8-K Exhibit 99.1
Jan 2025Month disclosedLynozyfic (linvoseltamab)REGNNDA/BLA submission—CompletedSEC 8-K Exhibit 99.1
September 27, 2024Dupixent (dupilumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
September 12, 2024Dupixent (dupilumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
August 26, 2024PAVBLU® (aflibercept)REGNFDA approval—ApprovedSEC Form 10-Q
August 20, 2024Lynozyfic (linvoseltamab-gcpt)REGNComplete Response Letter—CRL issuedFDA Complete Response Letters
Aug 2024Month disclosedLynozyfic (linvoseltamab)REGNComplete Response Letter—CRL issuedSEC Form 10-Q
April 5, 2024Libtayo (cemiplimab-rwlc)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
March 22, 2024Ordspono™ (odronextamab)REGNComplete Response Letterrelapsed/refractory FL and DLBCL dueCRL issuedSEC Form 10-Q
Every catalyst is quoted from REGN’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.